Skip to main content

Market Overview

Veru: Q3 Earnings Insights

Share:

Shares of Veru (NASDAQ:VERU) rose 4% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 25.00% year over year to ($0.05), which missed the estimate of ($0.03).

Revenue of $10,322,000 higher by 6.12% year over year, which missed the estimate of $10,970,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 13, 2020

Time: 08:00 AM

ET Webcast URL: https://verupharma.com/investors/

Price Action

Company's 52-week high was at $4.74

52-week low: $1.67

Price action over last quarter: down 24.38%

Company Overview

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.

 

Related Articles (VERU)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com